Brandes Investment Partners LP Has $33.50 Million Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Brandes Investment Partners LP boosted its position in shares of Smith & Nephew plc (NYSE:SNN - Free Report) by 11.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,363,039 shares of the medical equipment provider's stock after purchasing an additional 138,994 shares during the quarter. Brandes Investment Partners LP owned about 0.31% of Smith & Nephew worth $33,504,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SNN. Principal Securities Inc. raised its holdings in Smith & Nephew by 87.6% during the 4th quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 691 shares during the last quarter. R Squared Ltd bought a new stake in Smith & Nephew during the 4th quarter worth about $41,000. Hara Capital LLC raised its holdings in Smith & Nephew by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 1,957 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Smith & Nephew by 31.8% in the 4th quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider's stock valued at $73,000 after acquiring an additional 718 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Smith & Nephew by 26.0% in the 4th quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after acquiring an additional 1,213 shares during the last quarter. 25.64% of the stock is owned by institutional investors.

Remove Ads

Smith & Nephew Stock Down 1.4 %

Shares of SNN traded down $0.40 on Wednesday, hitting $28.37. The company's stock had a trading volume of 711,769 shares, compared to its average volume of 818,569. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The firm's fifty day moving average price is $26.52 and its 200-day moving average price is $27.09. Smith & Nephew plc has a fifty-two week low of $23.65 and a fifty-two week high of $31.72. The firm has a market capitalization of $12.40 billion, a price-to-earnings ratio of 13.13, a P/E/G ratio of 1.26 and a beta of 0.83.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be given a $0.447 dividend. The ex-dividend date is Friday, March 28th. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. Smith & Nephew's payout ratio is currently 41.20%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SNN. Canaccord Genuity Group reaffirmed a "hold" rating and issued a $27.00 price target on shares of Smith & Nephew in a research note on Monday. UBS Group cut Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Finally, StockNews.com raised Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $27.00.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.